Company news

Revvity, Inc. news in 2025

Revvity, Inc.'s news releases, calls and decks from 2025, newest first.

View company

Revvity to Present at J.P. Morgan Healthcare Conference

December 18, 2025

Revvity Introduces Signals Xynthetica, an AI-Augmented Design Platform for Molecular and Materials Discovery

December 16, 2025

Revvity Collaborates with MDIC and NIST to Launch New Somatic Cancer Reference Standards to Monitor Diagnostic Assay Accuracy

November 10, 2025

Revvity to Acquire ACD/Labs to Expand its Signals Software Capabilities

November 10, 2025

Revvity to Present at Upcoming Investor Conferences

October 28, 2025

Revvity Announces Financial Results for the Third Quarter of 2025

October 27, 2025

Revvity Showcases Progress with Purpose in 2025 Impact Report

October 14, 2025

Revvity to Hold Earnings Call on Monday, October 27, 2025

October 6, 2025

Revvity Announces Program to Revolutionize the Early Detection of Type 1 Diabetes

October 2, 2025

Revvity Unveils New AI Software Offering to Transform Preclinical Imaging Analysis

September 29, 2025

Revvity and Profluent Collaborate to Launch AI-Enhanced Adenine Deaminase Pin-point Base Editing Systems

September 22, 2025

Revvity Establishes In Vivo Imaging Center of Excellence in North Carolina

September 2, 2025

Revvity Launches Innovative Reagent Technology to Accelerate Development of Next-Generation Targeted Therapeutics

August 6, 2025

Revvity Announces Financial Results for the Second Quarter of 2025

July 28, 2025

Revvity to Hold Earnings Call on Monday, July 28, 2025

July 7, 2025

Revvity Introduces New IVD Reference Standards for Monitoring Oncology Diagnostic Testing Workflows

June 2, 2025

Revvity’s EUROIMMUN Unveils New Fully Automated Instrument for Specialty Testing

May 19, 2025

Revvity Announces Financial Results for the First Quarter of 2025

April 28, 2025

Revvity to Hold Earnings Call on Monday, April 28, 2025

April 3, 2025

Revvity Secures FDA Approval for Improved Automated Latent Tuberculosis Test

April 2, 2025

Revvity Expands Alliance with Genomics England to Drive Research into Newborn Genomic Sequencing in England

March 20, 2025

Revvity’s EUROIMMUN Receives CE Mark for Novel Measles Antibody Detection Assay

March 3, 2025

Revvity Wins Permanent Injunction Enforcing Agreements with Cloud Software Group

February 20, 2025

Calls in 2025

Decks in 2025